Sirnaomics Receives NCI Grant to Develop siRNA-Based Lung Cancer Rx | GenomeWeb

Sirnaomics this week announced that it has received a Small Business Innovation Research grant from the National Cancer Institute to develop novel siRNA-based therapeutics for lung cancer.

According to the NIH, the six-month grant began on June 1 and is worth $250,000. The company will use the funds to develop multi-targeted siRNA drugs for non-small cell lung cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.